Trials / Active Not Recruiting
Active Not RecruitingNCT04438824
Palbociclib and INCMGA00012 in People With Advanced Liposarcoma
A Phase II Study of CDK4/6 Inhibition (Palbociclib) Combined With PD-1 Blockade (INCMGA00012) in Patients With Advanced Well-differentiated Dedifferentiated Liposarcoma
- Status
- Active Not Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 42 (actual)
- Sponsor
- Memorial Sloan Kettering Cancer Center · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The researchers are doing this study to find out whether combining the study drugs palbociclib and INCMGA00012 is an effective and safe treatment for advanced liposarcoma. "Funding Source - FDA OOPD"
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | INCMGA00012 | INCMGA00012: 500 mg IV (flat dose) q28 days (+/- 7 days in each cycle) |
| DRUG | Palbociclib | Palbociclib:125 mg PO daily for 21 days, followed by 7 days off, q28 days |
Timeline
- Start date
- 2020-06-17
- Primary completion
- 2026-06-01
- Completion
- 2026-06-01
- First posted
- 2020-06-19
- Last updated
- 2025-10-14
Locations
7 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04438824. Inclusion in this directory is not an endorsement.